BIW 8962

Drug Profile

BIW 8962

Alternative Names: Anti-GM2 humanised antibody - Kyowa Hakko Kirin; BIW-8962

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyowa Hakko Kirin; Kyowa Hakko Kirin Korea
  • Developer BioWa; Kyowa Hakko Kirin Korea
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action G(M2) ganglioside inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 21 Oct 2016 Discontinued - Phase-II for Mesothelioma (Late-stage disease, Second-line therapy or greater) in South Korea (IV)
  • 21 Oct 2016 Discontinued - Phase-II for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top